-
Mashup Score: 0Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study - 7 month(s) ago
COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible to disruption by the pandemic, but few studies have evaluated the impact of the pandemic on clinical trial conduct.
Source: www.annalsofoncology.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
AbstractRenal cell carcinoma (RCC) of variant histology comprises approximately 20% of kidney cancer diagnoses, yet the optimal therapy for these patients and the factors that impact immunotherapy response remain largely unknown. To better understand the determinants of immunotherapy response in this population, we characterized blood- and tissue-based immune markers for patients with variant…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @CIR_AACR: Determinants of response to treatment in ncc RCC, by @ReneeSaliby, @TalalZarif1, Bakouny, Shah et al. https://t.co/pkJ1HQA5en…
-
-
Mashup Score: 0
Abstract. Renal cell carcinoma (RCC) of variant histology comprises approximately 20% of kidney cancer diagnoses, yet the optimal therapy for these patients and the factors that impact immunotherapy response remain largely unknown. To better understand the determinants of immunotherapy response in this population, we characterized blood- and tissue-based immune markers for patients with variant…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Huge congrats to @ReneeSaliby for this work now published in @CIR_AACR! Check out her awesome thread! Link: https://t.co/Pmpku8Of5Z Also thrilled to be a co-first author with @TalalZarif1 & @ShahValisha. Thankful to @BraunMDPhD, @DrRanaMcKay, @DrChoueiri, @LabSignoretti &… https://t.co/jupXzdalcW
-
-
Mashup Score: 1Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma - Nature Reviews Clinical Oncology - 11 month(s) ago
Renal cell carcinomas (RCCs) are generally immunogenic, but only a subset of patients receiving currently approved immune-checkpoint inhibitors have long-term disease remission. In this Review, the authors provide a conceptual framework for developing novel immunotherapy approaches, including an overview of the most promising novel immune checkpoints and antigen-directed therapies, and…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Finally highlighting how we can get to a cure with novel immunotherapy approaches including a shoutout to our @NatRevClinOncol @ASCO #ASCO23 @VanAllenLab @DrChoueiri @BraunMDPhD https://t.co/GpRKlu7CO5 https://t.co/7n1YOvdnEU
-
-
Mashup Score: 2IMG survey - 11 month(s) ago
Welcome to ASCO International Medical Graduates (IMG) Community of Practice! Your journey to success is the most important source of inspiration for IMGs in training or early stages of their careers. One of our goals is to get to know you and your path better. Please complete the below survey which only takes 5-7 minutes. THANK YOU!! ASCO IMG Community of Practice Note: We won’t share…
Source: Google DocsCategories: Latest Headlines, UrologyTweet-
Excited for this session that is fast approaching! Friday June 2nd 4-6 PM CST Room S103 at McCormick Place during #ASCO23 @DrChoueiri @NazliDizman @TarekHaykal1 @AyeshaButtMD @CharuAggarwalMD @ADesaiMD @GlopesMd @VivekSubbiah Please fill out our survey: https://t.co/j4tvlWBWS3 https://t.co/NDSvhS7yQF https://t.co/golqIcK5Hj
-
-
Mashup Score: 5Parsing clinical success rates - Nature Reviews Drug Discovery - 1 year(s) ago
Nature Reviews Drug Discovery – Parsing clinical success rates
Source: NatureCategories: Latest Headlines, UrologyTweet-
RT @VivekSubbiah: Parsing clinical success rates | Nature Reviews Drug Discovery https://t.co/BIQS199xay
-
-
Mashup Score: 6
Background Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that reflects the trajectory of evolution and influences clinical prognosis. Here, we seek to elucidate how ITH and tumor evolution during immune checkpoint inhibitor (ICI) treatment can lead to therapy resistance. Methods Here, we completed a single-arm pilot study to examine the safety and…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @arihakimi: Thrilled to be sharing our latest collaborative work with @illumina published in @GenomeMedicine https://t.co/NfJpECg4eD .…
-
-
Mashup Score: 15Glass | The First Digital Notebook Designed for Doctors - 1 year(s) ago
Glass Notebook is a knowledge management system tailored to the way doctors learn, organize, and curate medical knowledge.
Source: Glass NotebookCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @dereckwpaul: Another high-yield page from the https://t.co/kqEJm62rsO team to save to your notebooks! A 🔥 breakdown of the acute manag…
-
RT @dereckwpaul: Another high-yield page from the https://t.co/kqEJm62rsO team to save to your notebooks! A 🔥 breakdown of the acute manag…
-
RT @dereckwpaul: Another high-yield page from the https://t.co/kqEJm62rsO team to save to your notebooks! A 🔥 breakdown of the acute manag…
-
-
Mashup Score: 2Challenges facing IMGs in America - 1 year(s) ago
I host a roundtable of five guests—four first-timers and one recurring guest—to discuss the challenges of international medical graduates (IMGs) in oncology …
Source: YouTubeCategories: Latest Headlines, UrologyTweet-
RT @chadinabhan: Challenges facing IMGs in America https://t.co/rLoKpLJZVM via @YouTube The entire #HealthcareUnfiltered episode with the…
-
-
Mashup Score: 5
The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear.To…
Source: www.sciencedirect.comCategories: Latest Headlines, UrologyTweet-
Thank you @Cold_Steel_1970 @AdityaBagrodia @DrRanaMcKay for the awesome editorial about our paper in @EUplatinum on cytoreductive nephrectomy in metastatic RCC. @DrChoueiri @DrDanielHeng @TalalZarif1 @IMDConline Original paper: https://t.co/0YYOTJeRK5 https://t.co/7PX34pbywN
-
Join superstar @Chrislabaki1 to discuss clinical trial disruptions due to COVID19 with the @US_FDA! Many lessons learned during that period including with our #CCOS consortium @DrChoueiri @DDoroshow @MattGalsky @SheenaBhallaMD @Annals_Oncology https://t.co/31hlM0skeA https://t.co/Hd9NaCkyIX